Description: Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.
Home Page: www.atossatherapeutics.com
ATOS Technical Analysis
107 Spring Street
Seattle,
WA
98104
United States
Phone:
206 588 0256
Officers
| Name | Title |
|---|---|
| Dr. Steven C. Quay FCAP, M.D., Ph.D. | Chairman, CEO & Pres |
| Mr. Kyle Guse CPA, Esq., CPA | CFO, Gen. Counsel & Sec. |
| Ms. Heather Rees | VP of Fin. & Accounting |
| Ms. Delly Behen P.H.R. | VP of Admin. & HR |
| Ms. Janet Rose Rea MSPH, RAC | Sr. VP of Regulatory, Quality & Clinical Affairs |
| Dr. Richard Graydon M.D., Ph.D. | Interim Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6275 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2012-11-08 |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |